SE9904237D0 - New compound - Google Patents

New compound

Info

Publication number
SE9904237D0
SE9904237D0 SE9904237A SE9904237A SE9904237D0 SE 9904237 D0 SE9904237 D0 SE 9904237D0 SE 9904237 A SE9904237 A SE 9904237A SE 9904237 A SE9904237 A SE 9904237A SE 9904237 D0 SE9904237 D0 SE 9904237D0
Authority
SE
Sweden
Prior art keywords
conjugate
chondroadherin
arthitis
collagen
affecting pharmaceutical
Prior art date
Application number
SE9904237A
Other languages
Swedish (sv)
Inventor
Dick Heinegaard
Original Assignee
Ana Mar Diagnostics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ana Mar Diagnostics Ab filed Critical Ana Mar Diagnostics Ab
Priority to SE9904237A priority Critical patent/SE9904237D0/en
Publication of SE9904237D0 publication Critical patent/SE9904237D0/en
Priority to JP2001539475A priority patent/JP2003531109A/en
Priority to AU17486/01A priority patent/AU1748601A/en
Priority to EP00980190A priority patent/EP1237568A1/en
Priority to CA002392175A priority patent/CA2392175A1/en
Priority to PCT/SE2000/002293 priority patent/WO2001037861A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a conjugate of a collagen II-binding chondroadherin fragment and an arthritis-affecting pharmaceutical substance, such as a cytokine, a cytokine antagonist and/or a protease inhibitor. It has turned out that chondroadherin specifically interacts with collagen II thereby forming a complex. Release of cartilage extracellular matrix components, such as chondroadherin and collagen II is a symptom of arthitis. By providing a conjugate according to the present invention it is therefore possible to direct arthitis-affecting pharmaceutical substances directly to the pathogenic tissue. The inventive conjugate can be manufactured by chemical crosslinking. In case the arthitis-affecting pharmaceutical substance is a protein or a peptide, the conjugate can be a fusion protein and be produced by genetic engineering techniques.
SE9904237A 1999-11-22 1999-11-22 New compound SE9904237D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE9904237A SE9904237D0 (en) 1999-11-22 1999-11-22 New compound
JP2001539475A JP2003531109A (en) 1999-11-22 2000-11-22 Conjugates of collagen II binding fragments and arthritically active pharmaceutical substances
AU17486/01A AU1748601A (en) 1999-11-22 2000-11-22 A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance
EP00980190A EP1237568A1 (en) 1999-11-22 2000-11-22 A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance
CA002392175A CA2392175A1 (en) 1999-11-22 2000-11-22 A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance
PCT/SE2000/002293 WO2001037861A1 (en) 1999-11-22 2000-11-22 A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904237A SE9904237D0 (en) 1999-11-22 1999-11-22 New compound

Publications (1)

Publication Number Publication Date
SE9904237D0 true SE9904237D0 (en) 1999-11-22

Family

ID=20417825

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904237A SE9904237D0 (en) 1999-11-22 1999-11-22 New compound

Country Status (6)

Country Link
EP (1) EP1237568A1 (en)
JP (1) JP2003531109A (en)
AU (1) AU1748601A (en)
CA (1) CA2392175A1 (en)
SE (1) SE9904237D0 (en)
WO (1) WO2001037861A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003081838A (en) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd Glucosamine preparation
JP2007535517A (en) 2004-04-30 2007-12-06 アナマル・メデイカル・エイ・ビー Regulation of cartilage homeostasis
PL3715356T3 (en) * 2009-12-18 2024-03-11 Csl Limited Method of purifying polypeptides
CN102357259A (en) 2011-07-28 2012-02-22 王珊珊 Bioprotein sponge and preparation method thereof
EP2997040A4 (en) * 2013-05-14 2017-01-11 Haglund, Lisbet Chondroadherin fragments as indicators of intervertebral disc degeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635029A4 (en) * 1992-04-10 1996-01-24 Gen Hospital Corp Cartilage matrix protein and methods for use.
US5872094A (en) * 1993-01-06 1999-02-16 The General Hospital Corporation Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface

Also Published As

Publication number Publication date
JP2003531109A (en) 2003-10-21
CA2392175A1 (en) 2001-05-31
AU1748601A (en) 2001-06-04
EP1237568A1 (en) 2002-09-11
WO2001037861A1 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
ATE227739T1 (en) HYBRID PROTEIN FOR INHIBITING MAST CELL DEGRANULATION AND ITS USE
ATE437652T1 (en) USE OF HMGB1 TO ACTIVATE DENDRITIC CELLS
EA200400241A1 (en) MULTIMERAL CONTRAST SUBSTANCES BASED ON PEPTIDES ARE DIRECTED TO A TARGET
NO20031048D0 (en) "Pseudo" -native chemical ligation
DE69936103D1 (en) FUSION PROTEINS CONSISTING OF PROTEIN AND LIBRARY PEPTIDES
BR0314814A (en) Optimized variants of fc and methods for their generation
WO2002048195A3 (en) Engineered stimulus-responsive switches
NO20030856D0 (en) Membrane penetrating peptides and their use
DK1107996T3 (en) Human anti-factor IX / IXa antibodies
ATE397077T1 (en) SUBSTRATES AND EVIDENCE OF THE EFFECTIVENESS OF BETA-SECRETASE
SE9904237D0 (en) New compound
DE60139544D1 (en) MODIFIED, FLUORESCENT PROTEINS
DE60332579D1 (en) Process for immobilizing polypeptides via the carboxyl group of the C-terminus
SE0000675D0 (en) Monoclonal antibodies
ATE527545T1 (en) HCV ANTIGENS FOR MULTIPLE EPITO FUSION WITH MODIFIED PROTEOLYTIC CLEAVAGE SITE AND USES THEREOF
Cline et al. The structure of well‐folded β‐hairpin peptides promotes resistance to peptidase degradation
DK1234025T3 (en) Human enzymes from the metalloprotease family
ATE395602T1 (en) USE OF HMGB PROTEINS AND NUCLEIC ACIDS CODING THEREOF
ATE383878T1 (en) LIGHT-EMITTING FUSION PROTEINS AND DIAGNOSTIC AND THERAPEUTIC METHODS THEREOF
Lesner et al. Fluorescent analogs of trypsin inhibitor SFTI‐1 isolated from sunflower seeds—synthesis and applications
GB0319604D0 (en) Immobilization matrix for peptides and proteins
Attaran-Bandarabadi et al. Integrity of XIAP is essential for effective activity recovery of apoptosome and its downstream caspases by Smac/Diablo
PT723552E (en) OLIGOPEPTIDES DERIVED FROM REAGENT PROTEIN FRAGMENTS
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
DE602006017806D1 (en) TREATMENT OF NEURODE GENERATION